CasBio

CasBio

CasBio Therapeutics Pty. Ltd. is a three-and-a-half-year-old biotech or medtech start-up specialised in, but not limited to, CRISPR-Cas applications. The company has developed novel Cas13 and Cas12a proteins.

Cas12a and Cas13 are CRISPR-associated enzymes with distinct functionalities, both serving as valuable tools in molecular biology, particularly for diagnostics and gene editing. While CasBio is utilising Cas enzymes for therapeutic applications, it is also advancing their use in next-generation diagnostics by harnessing collateral cleavage activities.

Building on this capability, CasBio is developing CRISPR- and sensor-based Point-of-Care Testing (POCT) platforms to improve detection of infectious diseases in humans and animals. These diagnostics combine PCR-like sensitivity with speed and accessibility, delivering results in under an hour at the bedside, in clinics, farms, or in resource-limited settings.

The platform enables multiplex detection, resistance gene identification, and early diagnosis, making molecular testing as convenient as rapid tests but with laboratory-level accuracy.